Toujeo vs Lantus®
Efficacy and safety data vs Lantus®
A1C reduction was consistent with the BRIGHT primary endpoint.1,2
Comparable risk of hypoglycemia1,2
Limitations: This exploratory subgroup analysis was not designed or powered to detect differences between treatment groups.
The effect of renal impairment on the pharmacokinetics of Toujeo has not been studied. Frequent glucose monitoring and dose adjustment may be necessary.
†Baseline: 8.72% ± 0.83% for Toujeo, 8.57% ± 0.80% for Tresiba.3
‡At 24 weeks: 7.03% ± 0.79% for Toujeo, 7.03% ± 0.77% for Tresiba.3
Limitations: P values are for descriptive purposes only and are not adjusted for multiplicity.
Limitations: P values are for descriptive purposes only and are not adjusted for multiplicity.
Event rates were comparable for Maintenance Phase and Full Period.
§Anytime severe and/or confirmed hypoglycemia (<54 mg/dL).
Full period over 24 weeks (events per patient year)3,5
Limitations: P values are for descriptive purposes only and are not adjusted for multiplicity.
BRIGHT Study Design
A multicenter, open-label, randomized, active-controlled, two-arm, parallel-group, noninferiority study comparing the efficacy and safety of Toujeo and Tresiba U100 in adult insulin-naive patients with T2DM not adequately controlled with oral antidiabetic drug(s) ± a GLP-1 receptor agonist. Patients were randomized 1:1 to receive Toujeo (n=466) or Tresiba (n=463) subcutaneously between 6 PM and 8 PM over 24 weeks. The starting doses of Toujeo and Tresiba were 0.2 Units/kg and 10 Units once daily, respectively, in accordance with product label and the same insulin titration algorithm was followed. lnvestigational medicinal products (IMPs) were injected in the evening between 6 PM and 8 PM. Doses were adjusted at least weekly, but not more often than every 3 days, targeting a fasting self-monitored plasma glucose (SMPG) of 80 to 100 mg/dL while avoiding hypoglycemia. The aim of the titration period (Day 1 to Week 12) was the achievement of the fasting SMPG target.
The primary endpoint of this study was to demonstrate the noninferiority of Toujeo to Tresiba in A1C change from baseline to Week 24.3
Efficacy and safety data vs Lantus®
BRIGHT Renal subgroup analysis
And ordering made easy—register for and order samples with just a few clicks